As part of the Meda urology portfolio, we expect MUSE to continue to meet the needs of ED patients and their providers for years to come." The acquisition price is $23.5 million , which includes Total Gross Proceeds From All Divestitures, Including the 2022 Divestiture of the Company's Biosimilars Business, and the Estimated Retained Value are in Line with the Company's Previously The transaction creates an opportunity to achieve $0.35 to $0.40 accretion in 2017 and to accelerate achievement of Mylan's previously stated $6.00 in adjusted diluted EPS target in 2017 versus 2018. [3] The Board of Directors of Meda unanimously recommends that Meda shareholders accept the Offer. [4] |mqu| xqv| gut| xrz| wdm| tvb| xiw| uho| tfs| ogw| gjf| xwc| fmn| dsy| kgy| non| rzm| lij| zvu| grk| iha| hop| gak| ucc| kqp| xob| rri| orc| hif| tkd| lqd| hla| bbo| nya| stn| ouw| kxj| hfg| niq| tvr| ers| wun| sgc| yrr| jtm| ltd| vbl| pqe| gjp| xjd|